| In RNAi Move, Takeda Fronts $300M to Team Up on Arrowhead Liver Drug | Frank Vinluan | 10/08/20 | National |
| Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More | Frank Vinluan | 09/18/20 | National |
| Arrowhead Pharma Shares Soar on Early Liver Data for RNAi Drug | Frank Vinluan | 09/16/20 | Wisconsin |
| Bio Roundup: A Telehealth Combo, FDA’s BCMA OK, Biogen’s Bet & More | Sarah de Crescenzo | 08/07/20 | National |
| AstraZeneca Joins RNAi Mix, Pledging $80M to Silence Therapeutics | Frank Vinluan | 03/25/20 | Europe |
| Bio Roundup: So Long Celgene, RNAi’s Arrival, Pharma in 2020 & More | Frank Vinluan | 11/22/19 | National |
| Free of Baggage, Dicerna Cuts Another RNAi Deal and Gets $200M | Ben Fidler | 10/29/18 | Boston |
| Bio Roundup: Alzheimer’s Puzzle, ESMO Assessed, Drug Prices & More | Frank Vinluan | 10/26/18 | National |
| Biotech Roundup: Opioid News, ASH Preview, Boston Bio IPOs & More | Frank Vinluan | 11/03/17 | National |
| Despite Sanofi’s Help, MyoKardia Prices IPO Below Expectations | Ben Fidler | 10/29/15 | San Francisco |
| Amid Biotech Swoon, Third Rock’s MyoKardia Tees up IPO | Ben Fidler | 09/28/15 | San Francisco |
| East Coast Biotech Roundup: XTuit, Spero, Unum, RNAi Feud & More | Ben Fidler | 06/12/15 | Boston |
| Pop That Bubble: 5 Reasons Biotech Needs A Different Metaphor | Alex Lash | 04/14/15 | National |
| Big Events, Exits Raising Boston’s Innovation Profile at Year’s End | Gregory T. Huang | 12/12/14 | Boston |
| East Coast Biotech Roundup: Agios, Vertex, Epizyme, Celldex, & More | Ben Fidler | 11/21/14 | Boston |
| John Maraganore: From “Prototypical Geek” To Canny Alnylam Chief | Ben Fidler | 09/07/14 | Boston |
| With $310M and Public Investors Aboard, Is a Juno IPO Next? | Ben Fidler | 08/05/14 | Seattle |
| Radius Health Yanks IPO, Cites Market Conditions | Ben Fidler | 05/09/14 | Boston |
| Biotech IPO Slump Deepens as Alder Prices Below Range | Ben Fidler | 05/08/14 | Seattle |
| East Coast Biotech Roundup: Dicerna, J&J, Neurophage, & More | Ben Fidler | 01/31/14 | Boston |
| Dicerna Prices Upsized IPO at $15 Per Share, Starts Trading Thursday | Ben Fidler | 01/29/14 | Boston |
| East Coast Biotech Roundup: Scholar Rock, Dicerna, Eleven, & More | Ben Fidler | 01/03/14 | Boston |
| Dicerna Joins Biotech IPO Queue, Plans $69M Raise | Ben Fidler | 01/02/14 | Boston |
| East Coast Biotech Roundup: Cubist, Acetylon, Foundation, & More | Ben Fidler | 08/02/13 | Boston |
| Dicerna Snags $60M as RNAi Heats Up Again | Ben Fidler | 08/01/13 | Boston |
| Dicerna Pharmaceuticals Obtains $60,000,000 Series C Funding | VentureDeal | 08/01/13 | Boston |
| Shedding Baggage, Alnylam Turns a Corner | Steve Dickman | 02/21/13 | Boston |
| Infinity & Dicerna Among the Week’s Life Sciences Newsmakers | Erin Kutz | 08/10/12 | Boston |
| Boston Xconomists and Area Innovators Gather for Special Xconomy Event: The Photos | Erin Kutz | 10/13/11 | Boston |
| Tokai Snaps Up $23M From Novartis and Apple Tree to Challenge Leaders in Prostate Cancer | Luke Timmerman | 09/20/11 | Boston |
